A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial

Nomura, Akihiro; Tateno, Hiroki; Masaki, Katsunori; Muto, Tomoyasu; Suzuki, Shin; Satake, Kohta; Hida, Eisuke; Fukunaga, Koichi

doi:10.2196/12252

Cited by 14 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). A detailed study protocol was presented elsewhere 28 . Briefly, participants were recruited from 31 smoking cessation clinics in Japan, from October 2017 to January 2018, and allocated 1:1 to the CASC intervention group and the control group.…”

Section: Methodsmentioning

confidence: 99%

A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker

et al. 2020

Self Cite

View full text Add to dashboard Cite

Evidence of the long-term efficacy of digital therapies for smoking cessation that include a smartphone application (app) is limited. In this multi-center randomized controlled trial, we tested the efficacy of a novel digital therapy for smoking cessation: the "CureApp Smoking Cessation (CASC)" system, including a CASC smartphone app, a web-based patient management PC software for primary physicians, and a mobile exhaled carbon monoxide (CO) checker. A total of 584 participants with nicotine dependence were recruited from October 2017 to January 2018, and allocated 1:1 to the CASC intervention group or the control group. Both groups received a standard smoking cessation treatment with pharmacotherapy and counseling for 12 weeks. Meanwhile, the intervention group used the CASC system, and the control group used a control-app without a mobile CO checker, each for 24 weeks. The primary outcome was the biochemically validated continuous abstinence rate (CAR) from weeks 9 to 24. The main secondary outcome was an extended CAR from weeks 9 to 52. Except for 12 participants who did not download or use the apps, 285 participants were assigned to the intervention group, and 287, to the control. CAR from weeks 9 to 24 in the intervention group was significantly higher than that in the control group (63.9% vs. 50.5%; odds ratio [OR], 1.73; 95% confidence interval [CI], 1.24 to 2.42; P = 0.001). The CAR from weeks 9 to 52 was also higher in the intervention group than that in the control group (52.3% vs. 41.5%; OR, 1.55; 95% CI, 1.11 to 2.16; P = 0.010). No specific adverse events caused by the CASC system were reported. Augmenting standard face-to-face counseling and pharmacotherapy with a novel smartphone app, the CASC system significantly improved long-term CARs compared to standard treatment and a minimally supportive control app.

show abstract

Section: Methodsmentioning

confidence: 99%

A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…A previous single arm, prospective pilot study showed that the CASC, in addition to the standard program, led to significantly higher CAR from weeks 9 to 24 when compared with a historical control group [21]. Currently, there is an ongoing Phase III randomized controlled clinical trial to evaluate the efficacy of the CASC [20]. The standard smoking cessation program in Japan requires that patients’ exhaled CO concentration be measured at each clinic visit [5], and the information on their CO level is helpful for the primary doctor to give treatment advice on each visit.…”

Section: Discussionmentioning

confidence: 99%

“…The CASC consists of the following: (1) a CASC smartphone app for patients with nicotine dependence, (2) a mobile CO checker for patients, and (3) a Web-based patient management software for health care providers [20]. Participants are asked to watch a 5- to 10-min lecture on smoking cessation every day (see Multimedia Appendix 3 for the specifics).…”

Section: Methodsmentioning

confidence: 99%

“…The CureApp Smoking Cessation (CASC) is a novel smartphone app paired with a mobile CO checking device that was developed by CureApp Inc, Tokyo, Japan, to improve treatment success of the smoking cessation program for patients with nicotine dependence [19,20]. CASC can provide patients with accurate knowledge of nicotine dependency and tips for changing their behavior, as well as help them monitor their own exhaled CO levels with a personal mobile CO checking device at home.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparing Telemedicine and Face-to-Face Consultation Based on the Standard Smoking Cessation Program for Nicotine Dependence: Protocol for a Randomized Controlled Trial

Tanigawa¹,

Nomura²,

Kuroda³

et al. 2019

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

Background Smoking is a major public health concern. In Japan, a 12-week standard smoking cessation support program is available, however, its required face-to-face visits are a key obstacle in completing the program. Telemedicine is a useful way to provide medical treatment at a distance. Although telemedicine for smoking cessation using an internet-based video system has the potential for ensuring better clinical outcomes for patients with nicotine dependence, its efficacy is unclear. Objective The aim of this study is to determine the efficacy and feasibility of a smoking cessation support program using an internet-based video system compared with a face-to-face program among patients with nicotine dependence. Methods This study will be a randomized, controlled, open-label, multicenter trial. Participants randomized to the intervention arm will undergo an internet-based smoking cessation program, whereas control participants will undergo a standard face-to-face program. We will use the CureApp Smoking Cessation (CASC) for both arms, which consists of the CASC smartphone app for patients and a Web-based patient information management system for clinicians with a mobile carbon monoxide checking device. The primary endpoint will be the continuous abstinence rate (CAR) from weeks 9 to 12. Secondary endpoints will be: (1) the smoking cessation success rate at 4, 8, 12, and 24 weeks; (2) CAR from weeks 9 to 24; (3) changes in scores on the mood and physical symptoms scale and 12-Item French Version Of The Tobacco Craving Questionnaire; (4) Kano Test for Social Nicotine Dependence scores at 8, 12, and 24 weeks; (5) time to first lapse after the first visit; (6) nicotine dependence and cognition scale scores at 12 and 24 weeks; (7) usage rate of the CASC; (8) qualitative questionnaire about the usability and acceptability of telemedicine; and (9) presence of product problems or adverse events. Results We will recruit 114 participants who are nicotine-dependent but otherwise healthy adults from March to July 2018 and follow up with them until January 2019 (24 weeks). We expect all study results to be available by the end of March 2019. Conclusions This will be the first randomized controlled trial to evaluate the efficacy and feasibility of an internet-based (telemedicine) smoking cessation support program relative to a face-to-face program among patients with nicotine dependence. We expect that the efficacy of the telemedicine smoking cessation support program will not be clinically worse than the face-to-face program. If this trial demonstrates that telemedicine does not have clinically worse efficacy and feasibility than a conventional face-to-face program, physicians can begin to offer a more flexible smoking cessation program to patients who may otherwise give up on trying such programs. Trial Registration University Hospital Med...

show abstract

“…As information and communication technology (ICT) become increasingly central to our daily lives, development of digital health care and medicine has become a “hot” topic 9,10 . In the era of digital therapeutics (DTx), various trials using applications for chronic conditions such as nicotine dependence, 11,12 substance abuse, 13 or attention deficit hyperactivity disorder 14 have been initiated. In the case of hypertension management, several non‐pharmacological intermittent educational interventions have been well‐validated in previous studies.…”

Section: Introductionmentioning

confidence: 99%

A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB‐DH1 trial

Kario

Nomura

Harada

et al. 2020

J of Clinical Hypertension

Self Cite

View full text Add to dashboard Cite

show abstract

A Novel Smoking Cessation Smartphone App Integrated With a Mobile Carbon Monoxide Checker for Smoking Cessation Treatment: Protocol for a Randomized Controlled Trial

Cited by 14 publications

References 19 publications

A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker

A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker

Comparing Telemedicine and Face-to-Face Consultation Based on the Standard Smoking Cessation Program for Nicotine Dependence: Protocol for a Randomized Controlled Trial

A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB‐DH1 trial

Contact Info

Product

Resources

About